Articles with public access mandates - Mita libraLearn more
Not available anywhere: 4
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
E Chan, EL Kwak, J Hwang, M Heiskala, G de La Bourdonnaye, M Mita
Cancer Chemotherapy and Pharmacology 75, 701-709, 2015
Mandates: US National Institutes of Health
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
CC Lin, E Calvo, KP Papadopoulos, A Patnaik, J Sarantopoulos, AC Mita, ...
Cancer chemotherapy and pharmacology 63, 1065-1071, 2009
Mandates: US National Institutes of Health
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or …
J Sarantopoulos, AC Mita, JL Wade, JC Morris, O Rixe, MM Mita, ...
Cancer chemotherapy and pharmacology 74, 1113-1124, 2014
Mandates: US National Institutes of Health
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
AC Lockhart, S Sundaram, J Sarantopoulos, MM Mita, A Wang-Gillam, ...
Investigational new drugs 32, 1236-1245, 2014
Mandates: US National Institutes of Health
Available somewhere: 26
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
RG Maki, DR D'Adamo, ML Keohan, M Saulle, SM Schuetze, SD Undevia, ...
Journal of Clinical Oncology 27 (19), 3133-3140, 2009
Mandates: US National Institutes of Health
Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ...
JAMA oncology 5 (8), 1141-1149, 2019
Mandates: US National Institutes of Health
LXR/ApoE activation restricts innate immune suppression in cancer
MF Tavazoie, I Pollack, R Tanqueco, BN Ostendorf, BS Reis, ...
Cell 172 (4), 825-840. e18, 2018
Mandates: US Department of Defense, US National Institutes of Health, Howard Hughes …
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ...
JAMA oncology 5 (8), 1132-1140, 2019
Mandates: US National Institutes of Health
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC …
D Mahalingam, M Mita, J Sarantopoulos, L Wood, RK Amaravadi, ...
Autophagy 10 (8), 1403-1414, 2014
Mandates: US National Institutes of Health
Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation
JS Carew, EC Medina, JA Esquivel II, D Mahalingam, R Swords, K Kelly, ...
Journal of cellular and molecular medicine 14 (10), 2448-2459, 2010
Mandates: US National Institutes of Health
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...
Annals of oncology 33 (12), 1250-1268, 2022
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
HA Wakelee, A Patnaik, BI Sikic, M Mita, NL Fox, R Miceli, SJ Ullrich, ...
Annals of Oncology 21 (2), 376-381, 2010
Mandates: US National Institutes of Health
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors
C Sessa, GI Shapiro, KN Bhalla, C Britten, KS Jacks, M Mita, ...
Clinical Cancer Research 19 (13), 3671-3680, 2013
Mandates: Cancer Research UK
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels
D Mahalingam, EC Medina, JA Esquivel, CM Espitia, S Smith, K Oberheu, ...
Clinical cancer research 16 (1), 141-153, 2010
Mandates: US National Institutes of Health
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
D Mahalingam, S Goel, S Aparo, S Patel Arora, N Noronha, H Tran, ...
Cancers 10 (6), 160, 2018
Mandates: US National Institutes of Health
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer
JR Diamond, C Becerra, D Richards, A Mita, C Osborne, ...
Breast cancer research and treatment 184, 53-62, 2020
Mandates: US National Institutes of Health
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
AM Schram, L Gandhi, MM Mita, L Damstrup, F Campana, M Hidalgo, ...
British journal of cancer 119 (12), 1471-1476, 2018
Mandates: US National Institutes of Health
First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy
P Munster, M Mita, A Mahipal, J Nemunaitis, C Massard, T Mikkelsen, ...
Cancer management and research, 10463-10476, 2019
Mandates: US National Institutes of Health, Government of Spain
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
MH Voss, MS Gordon, M Mita, B Rini, V Makker, T Macarulla, DC Smith, ...
British journal of cancer 123 (11), 1590-1598, 2020
Mandates: US National Institutes of Health
Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies
G Falchook, S Rosen, P LoRusso, J Watts, S Gupta, CC Coombs, ...
Clinical Cancer Research 26 (6), 1247-1257, 2020
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program